P199 Mepolizumab improves and sustains asthma control and lung function in patients with severe asthma independent of baseline blood eosinophil count in the real world: results from REALITI-A at 2 years
Rattachement africain : it, us, be, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction and Objectives Preliminary 1-year analyses from the real-world REALITI-A study demonstrated mepolizumab improvements in asthma control and lung function, a key outcome measurement, with mepolizumab treatment across blood eosinophil count (BEC) levels, in patients with severe asthma. However, additional real-world evidence on the sustained effect of mepolizumab across BEC ranges is required. Methods REALITI-A was a 2-year, international, observational, prospective, single-arm study enrolling patients (≥18 years) with severe asthma, newly prescribed mepolizumab (100 mg subcutaneously). Changes from baseline in asthma control (Asthma Control Questionnaire-5 [ACQ-5] scores, minimal clinically important difference: 0.5) and lung function (forced expiratory volume in 1 second [FEV1]) were assessed for baseline BEC subgroups (<150, ≥150−<300, ≥300−<500, ≥500 cells/µL) at 1-year and 2-years post-mepolizumab exposure. Results 822 treated patients were included. ACQ-5 scores decreased from baseline to 2-years post-mepolizumab exposure across all BEC subgroups (figure 1; mean change from baseline [95% CI]: <150 cells/µL, -1.40 [-3.27, 0.47]; ≥150−<300 cells/µL, -1.76 [-2.34, -1.19]; ≥300−<500 cells/µL, -1.74 [-2.15, -1.33]; ≥500 cells/µL, -1.88 [-2.23, -1.53]). Improvements in ACQ-5 were sustained from 1-year post-exposure reductions (mean change from baseline at 1-year [95% CI]: -1.06 [-1.68, -0.44]; -1.19 [-1.81, -0.57]; -1.37 [-1.84, -0.90]; -1.65 [-2.01, -1.28], respectively). Lung function (FEV1) improved from baseline to Month 21–24 post-mepolizumab exposure for the BEC ≥300 cells/µL subgroups (figure 1; mean change from baseline [95% CI]: ≥300−<500 cells/µL, 261.5 [111.1, 411.9]) and ≥500 cells/µL, 275.6 [160.5, 390.6]), sustained from changes in FEV1 at Month 9–12 post-exposure (mean change from baseline [95% CI]: 130.1 [-3.4, -263.7] and 239.4 [141.7, 337.2], respectively). Improvements in lung function were less consistent in the BEC groups <300 cells/µL. Conclusions This analysis confirms treatment with mepolizumab in a real-life setting improves asthma control independent of baseline BEC, while lung function shows greater improvement with increased BEC; improvements observed at 1 year are maintained at 2 years.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- P199 Mepolizumab improves and sustains asthma control and lung function in patients with severe asthma independent of baseline blood eosinophil count in the real world: results from REALITI-A at 2 years
- Date Crossref
- 01/11/2025
- Éditeur
- BMJ Publishing Group Ltd and British Thoracic Society
- Type
- proceedings-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Humanitas University Department of Biomedical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins University Divisions of Allergy and Clinical Immunology pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins Medicine pays non établi dans la noticeÉtablissement de santé
-
Cliniques Universitaires Saint-Luc Department of Pulmonary Medicine pays non établi dans la noticeÉtablissement de santé
-
University of Glasgow pays non établi dans la noticeUniversité ou école supérieure
-
GlaxoSmithKline (United States) pays non établi dans la noticeEntreprise
-
Department of Clinical Immunology and Allergy pays non établi dans la noticeÉtablissement de santé
-
School of Infection and Immunity pays non établi dans la noticeUniversité ou école supérieure
-
Global Medical Affairs pays non établi dans la noticeInstitution
-
Collegeville GSK pays non établi dans la noticeUniversité ou école supérieure
Department of Biomedical Sciences — Humanitas University, Divisions of Allergy and Clinical Immunology — Johns Hopkins University et Johns Hopkins Medicine, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.